Global Induced Pluripotent Stem Cells Production Market Size To Exceed USD 3.15 Billion By 2033 l CAGR of 9.68%
Category: HealthcareGlobal Induced Pluripotent Stem Cells Production Market Size To Exceed USD 3.15 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Induced Pluripotent Stem Cells Production Market Size is to grow from USD 1.25 Billion in 2023 to USD 3.15 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 9.68% during the projected period.
Get more details on this report -
Browse key industry insights spread across 230 pages with 110 Market data tables and figures & charts from the report on the "Global Induced Pluripotent Stem Cells Production Market Size, Share, and COVID-19 Impact Analysis, By Process (Manual iPSC Production Process and Automated iPSC Production Process), By Product & Services (Products, Consumables & Kits, Instruments/ Devices, Automated Platforms, and Service), By Application (Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, and Others), By End-Use (Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Contract Research Organizations), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033" Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/induced-pluripotent-stem-cells-production-market
Induced Pluripotent Stem Cells (iPSCs) are a type of pluripotent stem cell derived from adult somatic cells. They are defined as differentiated cells that have been experimentally reprogrammed to an embryonic stem cell-like state. The distinct cell types differentiated from iPSCs can be used to mimic developmental processes in vitro, evaluate new drugs, and perform toxicity studies. The use of iPSCs for preclinical tests might cut the cost associated with providing animal models, which ultimately decreases the overall costs of the clinical trials. In the regenerative medicine field, iPSCs are used to derive disease-specific stem cells for study. Further, the urine-derived cells generation of iPSCs from a patient with spinal muscular atrophy with an Epi reprogramming vector (c-Myc-free and non-integrating) is combined with CRISPR technology to correct the disease-causing mutation at the iPSC level. The rising prevalence of cancer surges the market demand for induced pluripotent stem cell production for studying tumorigenesis. The increased application of iPSCs in neural drug discovery and development augments the market demand for induced pluripotent stem cells production. The increased interest in personalized medicine and surge in healthcare expenditure leveraging the market growth for induced pluripotent stem cells production. On the contrary, the strict regulatory compliance and high cost associated with stem cell therapies are restraining the global induced pluripotent stem cells production market. Further, the availability of alternatives for tumor treatment is hampering the market.
The manual iPSC production process segment is anticipated to hold the largest market share through the forecast period.
Based on the process, the global induced pluripotent stem cells production market is segmented into manual iPSC production process and automated iPSC production process. Among these, the manual iPSC production process segment is anticipated to hold the largest market share through the forecast period. Genes and transcription factors are inserted into developing somatic cells during the manual iPSC manufacturing process. This is followed by reprogramming, colony selection, iPSC expansion, and iPSC passaging. It is a precise and adaptable production technique that can meet diverse experimental needs.
The consumables & kits segment dominated the global induced pluripotent stem cells production market in 2023.
Based on the product & services, the global induced pluripotent stem cells production market is segmented into products, consumables & kits, instruments/ devices, automated platforms, and service. Among these, the consumables & kits segment dominated the global induced pluripotent stem cells production market in 2023. Key market players select media and other consumables, and end-users employ a range of induced pluripotent stem cell (iPSC) kits, such as reprogramming, differentiation, and generation kits, depending on the intended application. The adoption of iPSC technology for regenerative medicine and drug discovery is driving the market in the consumables & kits segment.
The drug development & discovery segment dominates the market with the largest revenue share in 2023.
Based on application, the global induced pluripotent stem cells production market is segmented into drug development & discovery, regenerative medicine, toxicology studies, and others. Among these, the drug development & discovery segment dominates the market with the largest revenue share in 2023. The creation of novel therapeutic strategies frequently makes use of induced pluripotent stem cells. The growing technical improvements for more targeted and efficient medication development procedures among chronic disease patients are upsurging the market growth.
The research & academic institutes segment dominated the global induced pluripotent stem cells production market in 2023.
Based on end-use, the global induced pluripotent stem cells production market is segmented into pharmaceutical & biotechnology companies, research & academic institutes, and contract research organizations. Among these, the research & academic institutes segment dominated the global induced pluripotent stem cells production market in 2023. iPSCs are being used in both clinical and research settings for regenerative investigations, which offers promising opportunities for bringing this technology into the clinic. The increasing interest in and investments made in stem cell therapy and research are driving the market for induced pluripotent stem cells production in the research & academic institutes segment.
North America dominates the market with the largest market share over the forecast period.
Get more details on this report -
North America dominates the market with the largest market share over the forecast period. The growing adoption of highly advanced technologies and systems in drug development, toxicity testing, and disease modeling, coupled with the growing acceptance of stem cell therapies are significantly contributing to market growth. The robust infrastructure for biotechnology R&D, and significant investment in iPSC research are driving the market in the region. Furthermore, the strong regulatory framework, and strategic collaboration among key market players in the region are driving the market in the region.
Asia-Pacific region is expected to grow the fastest during the forecast period. The better investment and rising prevalence of chronic diseases act as drivers for the induced pluripotent stem cells (iPSCs) market. The increasing research activities over stem cell therapies in the region with the growing biotechnology sector driving the market. Further, a wide range of clinical applications of induced pluripotent stem cells and emerging technological advancements of iPSCs have contributed to driving the market in the region.
Major vendors in the global induced pluripotent stem cells production market are Cynata Therapeutics, Evotec SE, Axol Biosciences Ltd., Lonza, FUJIFILM Cellular Dynamics, Inc., Ncardia, REPROCELLS, Inc., Thermo Fisher Scientific, Inc., Fate Therapeutics, Hitachi, Ltd., Merck KGaA, StemCellsFactory III, Applied StemCells, Inc., Pluricell Biotech, and Other Key Players.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Developments
- In November 2022, Prepaire announced a partnership with Ncardia to accelerate plans to discover new drugs and repurpose existing libraries. The new effort would launch efforts to design iPSCs by reprogramming adult cells (e.g., skin cells, blood cells) to an embryonic stem cell-like state, with the potential to become any cell type of the human body.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global induced pluripotent stem cells production market based on the below-mentioned segments:
Global Induced Pluripotent Stem Cells Production Market, Process Analysis
- Manual iPSC Production Process
- Automated iPSC Production Process
Global Induced Pluripotent Stem Cells Production Market, Product & Services Analysis
- Products
- Consumables & Kits
- Instruments/ Devices
- Automated Platforms
- Service
Global Induced Pluripotent Stem Cells Production Market, Application Analysis
- Drug Development & Discovery
- Regenerative Medicine
- Toxicology Studies
- Others
Global Induced Pluripotent Stem Cells Production Market, End-Use Analysis
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutes
- Contract Research Organizations
Global Induced Pluripotent Stem Cells Production Market, Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?